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ABSTRACT

Disclosed herein are therapies for treating or preventing reoccurrence of cancer. The therapies involved inhibition of
LIMKl in conjunction with AurKA inhibition. Specifically
exemplified herein is the administration of an AurKA inhibitor in conjunction with a LIMKl RNA interfering molecule.
4 Claims, 17 Drawing Sheets
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cells transfected with the empty vector.
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FIG. 2 LIMK1 Constructs
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Full length (LIMK), constitutively active phosphomimic (LIMKcA), LIMdomain only (LIMKL 0 ), and kinase-domain only (LIMKK0 ) LIMK1
constructs were cloned into the pCMV14 vector used for expression
in RWPE1 cells.
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Levels of pAurKA in PC3 Cells Treated with
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A:
PC3
cells
were
transfected
with
either
LIMK1 or control sh RNA. In
control shRNA transfected
cells, distinct localization of
pAurKA (green)
at the
spindle poles (red) could be
noted. In LIMK1 shRNA
treated cells, alpha-tubulin
staining
(red)
showed
disorganized
spindle
structure. Diffused
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CO-TARGETING OF AURORA A KINASE
AND LIM KINASE 1 FOR CANCER THERAPY

FIG. 4B shows that incubation of Aurora A with LIMKl
resulted in phosphorylation ofLIMKl at T508.
FIG. 5 Dual label immunofluorescence analysis shows that
LIMKl (red) and phospho AurKA (pAurKA) (green) colocalize to the centrosomes, which suggests their functional
cooperativity
FIG. 6 PC3 cells were transfected with LIMKl shRNA or
control shRNA and the levels of LIMKl and pAurKA were
detected by western blotting using anti-LIMKl or anti phospho-AurKA antibodies. GAPDH was used as the loading
control. The ratio of pAurKA to GAPDH levels was determined by densitometry (left panel).
FIG. 7 A: PC3 cells were transfected with either LIMKl or
control shRNA. In control shRNA transfected cells, distinct
localization of pAurKA (green) at the spindle poles (red)
could be noted. In LIMKl shRNA treated cells, alpha-tubulin
staining (red) showed disorganized spindle structure.
FIG. 7B: Knockdown ofLIMKl increased the number of
abnormal spindles in PC3 cells. PC3 cells were transfected
with either LIMKl or control shRNA and spindle abnormalities were quantified by counting 50 cells per treatment.
FIG. 8. Treatment with Aurora A kinase inhibitor
MLN8237 resulted in Mislocaliation of phosphoLIMKl and
phosphoAurK A: PC3 and RWPEl cells were treated with
MLN8237 (0.01 uM) for 24 hr or the vehicle (DMSO) for 72
hr. Immunofluorescence analysis showed that treatment with
MLN8237 caused mislocalization of pAurKA (green) and
improper spindle morphology (alpha-tubulin) (red). In addition, diffused staining and mislocalization of pLIMKl
(green) and centrin (red) in the nucleus were noted. The
vehicle control cells showed colocalization of pLIMKl with
centrin to the centrosomes (red). Aurora A Inhibition
Increased the Levels of phospho-Histone H3 suggesting
mitotic arrest (B). Western blot analysis of nuclear extracts
from PC3 cells treated with MLN8237 (0.01 uM). 1-tubulin
staining was used as the loading control. Aurora A Inhibition
Decreased Cell Survival (C). PC3 and RWPEl cells were
treated with MLN8237 (0.01 uM) MLN8237 for 24, 48, and
72 hr and cell viability was measured by MTT Assay.
FIG. 9 pertains to graphs presenting evidencing showing
that LIMKl inhibition potentiates the sensitivity of cells to an
AurKA inhibitor.
FIG. 10 pertains to graphs presenting additional evidencing showing that LIMKl inhibition potentiates the sensitivity
of cells to an AurKA inhibitor.
FIG. 11 pertains to graphs presenting further evidencing
showing that LIMKl inhibition potentiates the sensitivity of
cells to an AurKA inhibitor.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claims is related to U.S. Provisional
Application No. 61/357,652; filed Jun. 23, 2010. Priority to
this application is claimed under 35 USC 119 and is incorporated herein by reference in its entirety.
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SEQUENCE LISTING
The instant application contains a Sequence Listing which
has been submitted in ASCII format via EFS-Web and is
hereby incorporated by reference in its entirety. Said ASCII
copy, created on Sep. 23, 2011, is named 10669079.txt and is
505 bytes in size.
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BACKGROUND
Despite recent advances in development of improved cancer therapeutics one of the many clinical challenges is that
patients often show resistance to cancer drugs. This invention
provides evidence that an alternate method of treatment of
cancer could be adopted for improved efficacy of existing
therapies and/or treatment of drug resistant cancers. This
study describes a novel functional relationship between two
proteins that regulate proliferation of cells. Because these
proteins are involved in cell growth, the amounts of these
proteins are tightly regulated in normal cells however in cancer cells, abnormally increased amounts of these proteins are
noted. One of the common methods for controlling abnormal
growth of cancer cells is to inhibit production of these proteins. However, there are incidences of frequent development
of resistance to the chemotherapeutic agents upon prolonged
treatment, which sometimes is necessary to destroy all the
cancer cells in the body.
Aurora A kinase (AurKA), a serine/threonine kinase and a
member of Aurora kinase family, plays an essential role in
proper mitotic function. Full activation of AurKA requires
binding to the LIM domain containing protein. Earlier studies
have indicated a possible role of a LIM domain containing
serine/threonine and tyrosine kinase, LIM kinase 1 (LIMKl ),
in the mitotic process.
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a Western blot analysis showing expression
of AurKA and LIMKl in BPH and BPHL cells.
FIG. 2 shows a diagram of Full length (LIMK), constitutively active phosphomimic (LIMKCA), LIM-domain only
(LIMKLD), and kinase-domain only (LIMKKD) LIMKl
constructs.
FIG. 3 A: shows results of a Pull-down assay demonstrating an association between LIMK and Aurora A.
FIG. 3B: shows western blot results demonstrating that
Aurora A interacts with LIMKl in vivo.
FIG. 4 A: shows results of in vitro kinase assays demonstrating Aurora A phosphorylates inactive LIMKl in vitro.
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Disclosed herein are inventive embodiments that are based
on the discovery that inhibition of LIMKl in conjunction
AurKA inhibitors potentiates the sensitivity of cells to the
AurKA inhibitors. Accordingly, administration of anAurKA
inhibitor together with LIMKl inhibition will enable the use
oflesser amounts of individual inhibitor while obtaining the
same effect. Further, this will minimize the side effects of
individual drugs and possibly delay the process of development of drug-resistant cancers.
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Presented herein is evidence demonstrating a novel functional association between AurKA and LIMKl in cancer
cells, e.g., in prostate cancer cells. Overexpression ofLIMKl
in benign prostate hyperplasia (BPH-1) cells resulted in
increased expression of AurKA. Immunofluorescence analysis showed colocalization of phosphorylated LIMKl with
AurKA to the centrosomes in PC3 prostate cancer cells,
which naturally overexpress LIMKl. shRNA mediated
knockdown ofLIMKl decreased the level of phosphorylated
AurkA and caused disorganized spindle morphology with
phosphorylated AurKA localized to multiple spindle poles.
Immunoprecipitation and pull-down assays showed that
LIMKl and AurKA associate in a complex. Interaction
assays using deletion mutants ofLIMKl showed thatAurKA
binds to the LIM domains and the kinase domain independently in addition to the full-length LIMKl. LIMKl acts as a
substrate of AurKA and inhibition ofAurKA activity resulted
in mislocalization of phosphoLIMKl and the centrosomal
protein centrin.
The present disclosure indicates for the first time that
AurKA and LIMKl are functionally cooperating during
mitosis. Overexpression ofAurKA has been noted in a variety
of cancers including prostate cancer and currently, small mo!ecule inhibitors targeting AurKA are undergoing clinical trials. This study provides evidence that targeted inhibition of
LIMKl has the added benefit of functional inhibition of
AurKA.
Aurora kinase A inhibitors are currently undergoing phase
I and II clinical trials for cancer treatment but not all patients
respond to this drug as resistance to kinase inhibitors develops frequently. The results of the evidence herein also provides evidence that targeted inhibition of Aurora A kinase
may have the added benefit of also inhibiting LIMKl, and
vice versa.
Accordingly, A) combination therapy of AurKA and
LIMKl inhibitors will improve effectiveness of AurKA
inhibitors and B) inhibitors of LIMKl function may be used
for patients showing resistance to AurKA inhibitors. Furthermore, other inventive embodiments relate to the development
of inhibitors of LIMKl and use for combination therapy with
AurKA inhibitors or use singly for AurKA resistant cancers.
In one embodiment, a single interfering RNA targeting
LIMkl or AurKA mRNA is administered to decrease respective levels of each. In other embodiments, two or more interfering RNAs targeting the LIMKl and/or AurKA mRNA are
administered to decrease LIMKl and/or AurKA levels. In
certain embodiments, interfering RNA targeting LIMKl and/
or interfering RNA targeting AurKA are administered to the
subject sequentially or concurrently, thereby treating a related
cancer.
RNA interference (RNAi) is a process by which doublestranded RNA (dsRNA) is used to silence gene expression.
While not wanting to be bound by theory, RNAi begins with
the cleavage of longer dsRNAs into small interfering RNAs
(siRNAs) by an RNaseIII-like enzyme, dicer. SiRNAs are
dsRNAs that are usually about 19 to 28 nucleotides, or 20 to
25 nucleotides, or 21 to 22 nucleotides in length and often
contain 2-nucleotide 3' overhangs, and 5' phosphate and 3'
hydroxyl termini. One strand of the siRNA is incorporated
into a ribonucleoprotein complex known as the RNA-induced
silencing complex (RISC). RISC uses this siRNA strand to

identify mRNA molecules that are at least partially complementary to the incorporated siRNA strand, and then cleaves
these target mRNAs or inhibits their translation. Therefore,
the siRNA strand that is incorporated into RISC is known as
the guide strand or the antisense strand. The other siRNA
strand, known as the passenger strand or the sense strand, is
eliminated from the siRNA and is at least partially homologous to the target mRNA. Those of skill in the art will recognize that, in principle, either strand of an siRNA can be
incorporated into RISC and function as a guide strand. However, siRNA design (e.g., decreased siRNA duplex stability at
the 5' end of the desired guide strand) can favor incorporation
of the desired guide strand into RISC.
The antisense strand of an siRNA is the active guiding
agent of the siRNA in that the antisense strand is incorporated
into RISC, thus allowing RISC to identify target mRNAs with
at least partial complementarity to the antisense siRNA strand
for cleavage or translational repression. RISC-related cleavage of mRNAs having a sequence at least partially complementary to the guide strand leads to a decrease in the steady
state level of that mRNA and of the corresponding protein
encoded by this mRNA. Alternatively, RISC can also
decrease expression of the corresponding protein via translational repression without cleavage of the target mRNA.
The GenBank database provides the DNA sequence for
LIMKl as accession no. NM_002314. Equivalents of the
above cited LIMkl mRNA sequence are alternative splice
forms, allelic forms, isozymes, or a cognate thereof. A cognate is a LIMKl mRNA from another manimalian species
that is homologous to the cited human form (i.e., an ortholog).
The GenBank database provides the DNA sequence for
AurKA as accession no NM_l9843. Equivalents of the
above cited AurKA mRNA sequence are alternative splice
forms, allelic forms, isozymes, or a cognate thereof. A cognate AurKA mRNA from another mammalian species that is
homologous to the cited human form.
The term "siRNA" as used herein refers to a doublestranded interfering RNA unless otherwise noted. Typically,
an siRNA of the invention is a double-stranded nucleic acid
molecule comprising two nucleotide strands, each strand having about 19 to about 28 nucleotides (i.e. about 19, 20, 21, 22,
23, 24, 25, 26, 27, or 28 nucleotides). The phrase "interfering
RNA having a length of 19 to 49 nucleotides" when referring
to a double-stranded interfering RNA means that the antisense and sense strands independently have a length of about
19 to about 49 nucleotides, including interfering RNA molecules where the sense and antisense strands are connected by
a linker molecule.
In addition to siRNA molecules, other interfering RNA
molecules and RNA-like molecules can interact with RISC
and silence gene expression. Examples of other interfering
RNA molecules that can interact with RISC include short
hairpin RNAs (shRNAs), single-stranded siRNAs, microRNAs (miRNAs), and dicer-substrate 27-mer duplexes.
Examples of RNA-like molecules that can interact with RISC
include siRNA, single-stranded siRNA, microRNA, and
shRNA molecules containing one or more chemically modified nucleotides, one or more non-nucleotides, one or more
deoxyribonucleotides, and/or one or more non-phosphodiester linkages. All RNA or RNA-like molecules that can
interact with RISC and participate in RISC-related changes in
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gene expression are referred to herein as "interfering RNAs"
or "interfering RNA molecules." SiRNAs, single-stranded
siRNAs, shRNAs, miRNAs, and dicer-substrate 27-mer
duplexes are, therefore, subsets of "interfering RNAs" or
"interfering RNA molecules."
Single-stranded interfering RNA has been found to effect
mRNA silencing, albeit less efficiently than double-stranded
RNA. Therefore, embodiments of the present invention also
provide for administration of a single-stranded interfering
RNA that has a region of at least near-perfect contiguous
complementarity with a portion of the LIMKl mRNA or
AurKA mRNA. The single-stranded interfering RNA has a
length of about 19 to about 49 nucleotides as for the doublestranded interfering RNA cited above. The single-stranded
interfering RNA has a 5' phosphate or is phosphorylated in
situ or in vivo at the 5' position. The term "5' phosphorylated"
is used to describe, for example, polynucleotides or oligonucleotides having a phosphate group attached via ester linkage to the CS hydroxyl of the sugar (e.g., ribose, deoxyribose,
or an analog of same) at the 5' end of the polynucleotide or
oligonucleotide.
Single-stranded interfering RNAs can be synthesized
chemically or by in vitro transcription or expressed endogenously from vectors or expression cassettes as described
herein in reference to double-stranded interfering RNAs. 5'
Phosphate groups may be added via a kinase, or a 5' phosphate may be the result of nuclease cleavage of an RNA. A
hairpin interfering RNA is a single molecule (e.g., a single
oligonucleotide chain) that comprises both the sense and
antisense strands of an interfering RNA in a stem-loop or
hairpin structure (e.g., a shRNA). For example, shRNAs can
be expressed from DNA vectors in which the DNA oligonucleotides encoding a sense interfering RNA strand are
linked to the DNA oligonucleotides encoding the reverse
complementary antisense interfering RNA strand by a short
spacer. If needed for the chosen expression vector, 3' terminal
T's and nucleotides forming restriction sites may be added.
The resulting RNA transcript folds back onto itself to form a
stem-loop structure.
Nucleic acid sequences cited herein are written in a 5' to 3'
direction unless indicated otherwise. The term "nucleic acid,"
as used herein, refers to either DNA or RNA or a modified
form thereof comprising the purine or pyrimidine bases
present in DNA (adenine "A," cytosine "C," guanine "G,"
thymine "T") or in RNA (adenine "A," cytosine "C," guanine
"G," uracil "U"). Interfering RNAs provided herein may
comprise "T" bases, particularly at 3' ends, even though "T"
bases do not naturally occur in RNA. "Nucleic acid" includes
the terms "oligonucleotide" and "polynucleotide" and can
refer to a single-stranded molecule or a double-stranded mo!ecule. A double-stranded molecule is formed by WatsonCrick base pairing betweenA and T bases, C and G bases, and
between A and U bases. The strands of a double-stranded
molecule may have partial, substantial or full complementarity to each other and will form a duplex hybrid, the strength
of bonding of which is dependent upon the nature and degree
of complementarity of the sequence of bases.
In certain embodiments, interfering RNA target sequences
(e.g., siRNA target sequences) within a target mRNA
sequence are selected using available design tools. Interfering
RNAs corresponding to a LIMKl or AurKA target sequence

are then tested in vitro by transfection of cells expressing the
target mRNA followed by assessment of knockdown as
described herein. The interfering RNAs can be further evaluated in vivo using animal models as described herein.
Techniques for selecting target sequences for siRNAs are
provided, for example, by Tuschl, T. et al., "The siRNA User
Guide," revised May 6, 2004, available on the Rockefeller
University web site; by Technical Bulletin #506, "siRNA
Design Guidelines," Ambion Inc. atAmbion's web site; and
by other web-based design tools at, for example, the Invitrogen, Dharmacon, Integrated DNA Technologies, Genscript,
or Proligo web sites. Initial search parameters can include
G/C contents between 35% and 55% and siRNA lengths
between 19 and 27 nucleotides. The target sequence may be
located in the coding region or in the 5' or 3' untranslated
regions of the mRNA. The target sequences can be used to
derive interfering RNA molecules, such as those described
herein.
In a specific embodiment, the interfering RNA targeting
LIMKl is AAGGACAAGAGGCTCAACTTCATCACTGA
(SEQ ID NO. 1)
It has been discovered that Aurora A induces phosphorylation of LIMKl at T508 and Aurora A kinase and LIMKl
colocalize to the centrosomes. LIMKl also phosphorylates
AurKA and knockdown ofLIMKl reduces the level of phosphorylated Aurora A. Knockdown of LIMKl further causes
mislocalization of Aurora A kinase and disorganized spindle
structure. The inventors work shows that Aurora A kinase and
LIMKl are functionally cooperative during mitosis.
As used herein, the term "effective amount" refers to the
amount of a therapy that is sufficient to result in the prevention of the development, recurrence, or onset of cancer and
one or more symptoms thereof, to enhance or improve the
prophylactic effect( s) of another therapy, reduce the severity,
the duration of cancer, ameliorate one or more symptoms of
cancer, prevent the advancement of cancer, cause regression
of cancer, and/or enhance or improve the therapeutic effect(s)
of another therapy. In an embodiment of the invention, the
amount of a therapy is effective to achieve one, two, three or
more of the following results following the administration of
one, two, three or more therapies: (1) a stabilization, reduction or elimination of the cancer stem cell population; (2) a
stabilization, reduction or elimination in the cancer cell population; (3) a stabilization or reduction in the growth of a tumor
or neoplasm; (4) an impairment in the formation of a tumor;
(5) eradication, removal, or control of primary, regional and/
or metastatic cancer; (6) a reduction in mortality; (7) an
increase in disease-free, relapse-free, progression-free, and/
or overall survival, duration, or rate; (8) an increase in the
response rate, the durability of response, or number of
patients who respond or are in remission; (9) a decrease in
hospitalization rate; (10) a decrease in hospitalization
lengths; (11) the size of the tumor is maintained and does not
increase or increases by less than 10%, preferably less than
5%, preferably less than 4%, preferably less than 2%; (12) an
increase in the number of patients in remission; (13) an
increase in the length or duration of remission; (14) a decrease
in the recurrence rate of cancer; (15) an increase in the time to
recurrence of cancer; and (16) an amelioration of cancerrelated symptoms and/or quality of life.
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As used herein, the terms "subject" and "patient" are used
interchangeably. As used herein, the term "subject" refers to
an animal, preferably a marmnal such as a non-primate (e.g.,
cows, pigs, horses, cats, dogs, rats etc.) and a primate (e.g.,
monkey and human), and most preferably a human. In some
embodiments, the subject is a non-human animal such as a
farm animal (e.g., a horse, pig, or cow) or a pet (e.g., a dog or
cat). In a specific embodiment, the subject is an elderly
human. In another embodiment, the subject is a human adult.
In another embodiment, the subject is a human child. In yet
another embodiment, the subject is a human infant.
As used herein, the term "therapeutic agent" refers to any
molecule, compound, and/or substance that is used for the
purpose of treating and/or managing cancer. Examples of
therapeutic agents include, but are not limited to, proteins,
immunoglobulins (e.g., multi-specific Igs, single chain Igs, lg
fragments, polyclonal antibodies and their fragments, monoclonal antibodies and their fragments), antibody conjugates
or antibody fragment conjugates, peptides (e.g., peptide
receptors, selectins ), binding proteins, chemospecific agents,
chemotoxic agents (e.g., anti-cancer agents), radiation, chemotherapy, anti-angiogenic agents, and small molecule
drugs. Therapeutic agents may be a(n) anti-angiogenesis
therapy, targeted therapy, radioimmunotherapy, small molecule therapy, biologic therapy, epigenetic therapy, toxin
therapy, differentiation therapy, pro-drug activating enzyme
therapy, antibody therapy, chemotherapy, radiation therapy,
hormonal therapy, immunotherapy, or protein therapy.
As used herein, the terms "therapies" and "therapy" can
refer to any method(s), composition(s), and/or agent(s) that
can be used in the treatment of a cancer or one or more
symptoms thereof. In certain embodiments, the terms
"therapy" and "therapies" refer to chemotherapy, radiation
therapy, radioimmunotherapy, hormonal therapy, targeted
therapy, toxin therapy, pro-drug activating enzyme therapy,
protein therapy, antibody therapy, small molecule therapy,
epigenetic therapy, demethylation therapy, histone deacetylase inhibitor therapy, differentiation therapy, antiangiogenic
therapy, biological therapy including immunotherapy and/or
other therapies useful in the treatment of a cancer or one or
more symptoms thereof.
As used herein, the terms "treat", "treatment'', and "treating" in the context of the administration of a therapy to a
subject refer to the reduction or inhibition of the progression
and/or duration of cancer, the reduction or amelioration of the
severity of cancer, and/or the amelioration of one or more
symptoms thereof resulting from the administration of one or
more therapies. In a specific embodiment, a patient that is at
a high risk for developing cancer is treated, i.e., a patient that
has been diagnosed with aAurKa or Limkl positive precancerous lesion. In specific embodiments, such terms refer to
one, two, or three or more results following the administration
of one, two, three or more therapies: (1) a stabilization, reduction or elimination of the cancer stem cell population; (2) a
stabilization, reduction or elimination in the cancer cell population; (3) a stabilization or reduction in the growth of a tumor
or neoplasm; (4) an impairment in the formation of a tumor;
( 5) eradication, removal, or control of primary, regional and/
or metastatic cancer; (6) a reduction in mortality; (7) an
increase in disease-free, relapse-free, progression-free, and/
or overall survival, duration, or rate; (8) an increase in the

response rate, the durability of response, or number of
patients who respond or are in remission; (9) a decrease in
hospitalization rate; (10) a decrease in hospitalization
lengths; (11) the size of the tumor is maintained and does not
increase or increases by less than 10%, preferably less than
5%, preferably less than 4%, preferably less than 2%; (12) an
increase in the number of patients in remission; (13) an
increase in the length or duration of remission; (14) a decrease
in the recurrence rate of cancer; (15) an increase in the time to
recurrence of cancer; and (16) an amelioration of cancerrelated symptoms and/or quality of life. In certain embodiments, such terms refer to a stabilization or reduction in the
cancer stem cell population. In some embodiments, such
terms refer to a stabilization or reduction in the growth of
cancer cells. In some embodiments, such terms refer to a
stabilization or reduction in the cancer stem cell population
and a reduction in the cancer cell population. In some
embodiments, such terms refer to a stabilization or reduction
in the growth and/or formation of a tumor. In some embodiments, such terms refer to the eradication, removal, or control
of primary, regional, or metastatic cancer (e.g., the minimization or delay of the spread of cancer). In some embodiments, such terms refer to a reduction in mortality and/or an
increase in survival rate of a patient population. In further
embodiments, such terms refer to an increase in the response
rate, the durability of response, or number of patients who
respond or are in remission. In some embodiments, such
terms refer to a decrease in hospitalization rate of a patient
population and/or a decrease in hospitalization length for a
patient population.
The present invention also provides methods for treating
cancer, the methods comprising administering to a patient
(e.g., a human patient) in need thereof, a therapeutically
effective regimen, the regimen comprising administering to
the patient an inhibitor ofLIMKl and an inhibitor of AurKA,
or an inhibitor that inhibits both LIMKl and AurKA, and
optionally one or more additional therapies, said additional
therapy not being compounds of the invention. The compound of the invention and the additional therapy can be
administered separately, concurrently, or sequentially. The
combination of agents can act additively or synergistically.
PCT/USl0/35800; filed May 21, 2010 is cited herein in its
entirety, and specifically for a teaching of the many additional
therapies that may be administered in conjunction with
LIMKl and/or AurKA inhibitors, or LIMKl/AurKA inhibitors. U.S. Patent Publication 20100144783 is cited to for
examples ofknownAurKA inhibitors, as well as an exposition on the number of cancers that may be treated according to
the compounds and methods of the invention. U.S. Patent
Publication 20100120771 is cited for AurKA inhibitors.
Macdonald et al. Mo! CancerTher, 7:3490 (2008) is cited for
teaching of LIMKl inhibitors and methodology for indentifying such inhibitors, and U.S. App No. 12/706,218 is cited
for teachings of LIMKl inhibitors.
In general, compounds of the invention will be administered in therapeutically effective amounts via any of the usual
and acceptable modes known in the art, either singly or in
combination with one or more therapeutic agents. A therapeutically effective amount may vary widely depending on
the severity of the disease, the age and relative health of the
subject, the potency of the compound used and other factors.
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In general, satisfactory results are indicated to be obtained
systemically at daily dosages of from about 0.03 to 2.5 mg/kg
per body weight. An indicated daily dosage in the larger
mammal, e.g. humans, is in the range from about 0.5 mg to
about 1000 mg, conveniently administered, e.g. in divided
doses up to four times a day or in retard form. Suitable unit
dosage forms for oral administration comprise from ca. 1 to
1000 mg active ingredient. In view of the inventor's discovery
that LIMKl and AurKA inhibitors can work together synergistically, this will allow dosages of each to be administered
at lower levels than that required for usage of only one or the
other classes of inhibitors. Synergy refers to the additive
effect of using a dose of another inhibitor that is not achieved
by using the same dose of the same inhibitor. This is believed
to lessen the possible toxicity that may be experienced with
higher doses of a certain inhibitor. For example, if 100 mg is
a determined daily dosage for only a AurKA inhibitor, then
only 45 mg daily dosage of the AurKA inhibitor may be
needed when 45-50 mg of a LIMKl inhibitor is administered
in combination to achieve the same treatment effect.
Pharmaceutical compositions of the invention can be
administered by any number of routes including, but not
limited to, oral, intravenous, intramuscular, intra-arterial,
intramedullary, intrathecal, intraventricular, transdermal,
subcutaneous, intraperitoneal, intranasal, parenteral, topical,
sub lingual, or rectal means. Pharmaceutical compositions for
oral administration can be formulated using pharmaceutically
acceptable carriers well known in the art in dosages suitable
for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees,
capsules, liquids, gels, syrups, slurries, suspensions, and the
like, for ingestion by the patient.
In addition to the active ingredients, these pharmaceutical
compositions can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which
facilitate processing of the active compounds into preparations which can be used pharmaceutically.
Pharmaceutical compositions comprising a compound of
the present invention in free form or in a pharmaceutically
acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent may be manufactured
in a conventional marmer by mixing, granulating or coating
methods. For example, oral compositions may be tablets or
gelatin capsules comprising the active ingredient together
with a) diluents, e.g., lactose, dextrose, sucrose, mannitol,
sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica,
talcum, stearic acid, its magnesium or calcium salt and/or
polyethyleneglycol; for tablets, together with c) binders, e.g.,
magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/
orpolyvinylpyrrolidone; and if desired, d) disintegrants, e.g.,
starches, agar, alginic acid or its sodium salt, or effervescent
mixtures; and/ore) absorbents, colorants, flavors and sweeteners. Injectable compositions may be aqueous isotonic solutions or suspensions, and suppositories may be prepared from
fatty emulsions or suspensions.

antibodies. GAPDH expression was used as the loading control. BPHLCA pertains to BPH-1 cells expressing Flagtagged phosphomimic LIMKl (constitutively active), BPHV
pertains to cellsBPH-1 cells transfected with the empty vector. Cells expressing the LIMKl phosphomic exhibited
greater AurKA expression.
Example 2
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FIG. 3A shows the results of a Pull-down assay. Whole cell
lysates from RWPE-1 cells transiently transfected with
LIMK (RWPElL), LIMKLD (RWPElLLD), or LIMKKD
(RWPElLKD) were incubated with recombinant His-tagged
Aurora A bound to magnetic His-bind beads. Pull-down of
LIMKl was detected by western blotting using anti-Flag
antibodies. FIG. 3B shows that Aurora A interacts with
LIMKl in vivo. FIG. 3B provides western blots of AurKA or
Flag-tagged LIMKl in total cell extracts (Tot. extracts),
FLAG immunoprecipitates, AurKA immunoprecipitates and
rabbit IgG immunoprecipitates of total cell extracts prepared
from BPHLCA and BPHV cells. An association between
AurKA and LIMKl is demonstrated in these western blots.
Example 4
FIG. 4 shows that Aurora A phosphorylates inactive
LIMKl in vitro. In vitro kinase assays were performed using
recombinant GST-Aurora A kinase and GST-LIMKl. 32P
incorporation was detected by autoradiography. B: Incubation of Aurora A with LIMKl resulted in phosphorylation of
LIMKl at T508. Whole cell extracts from RWPE-1 cells
transiently expressing LIMKl was treated with phosphatase
and LIMKl was immunoprecipitated using anti-Flag antibodies. Precipitates were then incubated in kinase assay
buffer and cold ATP with or without recombinant AurKA.
Phosphorylation at T508 was detected by western blotting
using phospho-specific LIMKl (T508) antibodies.
Example 5

55

FIG. 5 Dual label immunofluorescence analysis shows that
LIMKl (red) and phospho AurKA (pAurKA) (green) colocalize to the centrosomes. This suggests that these two
enzymes possess functional cooperativity with eachother.
Example 6
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EXAMPLES
Example 1
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FIG. 1 Western blot analysis of the total cell extracts from
BPHV or BPHLCA cells using anti-LIMKl or anti-AurKA

FIG. 2 shows diagrams of full length (LIMK), constitutively active phosphomimic (LIMKCA), LIM-domain only
(LIMKLD), and kinase-domain only (LIMKKD) LIMKl
constructs. These constructs were cloned into the pCMV14
vector used for expression in RWPEl cells.

FIG. 6 PC3 cells were transfected with LIMKl shRNA or
control shRNA and the levels of LIMKl and pAurKA were
detected by western blotting using anti-LIMKl or anti phospho-AurKA antibodies. GAPDH was used as the loading
control. The ratio of pAurKA to GAPDH levels was determined by densitometry (left panel).
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Example 7

with concentration of inhibitor. LIMKl knockdown appeared
to increase sensitivity at lower inhibitor concentrations.

FIG. 7 A: PC3 cells were transfected with either LIMKl or
control shRNA. In control shRNA transfected cells, distinct
localization of pAurKA (green) at the spindle poles (red)
could be noted. In LIMKl shRNA treated cells, alpha-tubulin
staining (red) showed disorganized spindle structure. Diffused B: Knockdown of LIMKl increased the number of
abnormal spindles in PC3 cells. PC3 cells were transfected
with either LIMKl or control shRNA and spindle abnormalities were quantified by counting 50 cells per treatment.
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Example 8
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FIG. 8. Treatment with Aurora A kinase inhibitor
MLN8237 resulted in Mislocaliation of phosphoLIMKl and
phosphoAurK A: PC3 and RWPEl cells were treated with
MLN8237 (0.01 uM) for 24 hr or the vehicle (DMSO) for 72
hr. Immunofluorescence analysis showed that treatment with
MLN8237 caused mislocalization of pAurKA (green) and
improper spindle morphology (alpha-tubulin) (red). In addition, diffused staining and mislocalization of pLIMKl
(green) and centrin (red) in the nucleus were noted. The
vehicle control cells showed colocalization of pLIMKl with
centrin to the centrosomes (red). Aurora A Inhibition
Increased the Levels of phospho-Histone H3 suggesting
mitotic arrest (B). Western blot analysis of nuclear extracts
from PC3 cells treated with MLN8237 (0.01 uM). Y-tubulin
staining was used as the loading control. Aurora A Inhibition
Decreased Cell Survival (C). PC3 and RWPEl cells were
treated with MLN8237 (0.01 uM) MLN8237 for 24, 48, and
72 hr and cell viability was measured by MTT Assay.
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Example 9
Inhibition of LIMKl has a synergistic effect on treatment
withAurKA inhibitor MLN8237
Experimental Procedure:
10 cm dishes were transiently transfected with 6 ug of
LIMKl shRNA or control shRNA. 24 hrs post transfection,
untransfected PC3 cells along with the transfected PC3 cells
were seeded in 96 well plates in triplicate (5,000 cells/well).
14 hrs after seeding, media was changed to MLN8237 containing media, at concentrations of 0.001 uM, 0.01 uM, and
0.1 uM. After 24 and 48 hours of inhibitor treatment, cell
proliferation was measured using MTS assay. MTS reagent
was added to each well and allowed to incubate for 3 hrs at 3 7°
C. before reading absorbances. Absorbances were compared
against controls.
Results:
Results for this example are shown in FIGS. 9-11. Untransfected PC3 cells were most sensitive to 0.1 uM MLN823 7 at
48 hrs. Inhibition seemed to be linear and increased with time.
Untransfected PC3 cells were less sensitive than the transfected cells.
PC3 cells transfected with LIMKl shRNA experienced
more sensitivity to MLN8237 than those cells transfected
with the control shRNA. The number of viable cells in both
transfected samples decreased with time and concentration of
MLN8237, although the relative difference in viable cells
between the control and LIMKl shRNA was not consistent
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At 48 hrs: 0.001 uM treatment resulted in LIMKl knockdown wells having only 7 5% of the number of viable cells
compared to control shRNA. While in the 0.1 uM treatment,
LIMKl knockdown wells had 83% of the number of viable
cells compared to the control shRNA.
When compared with untransfected PC3 cells treated with
the vehicle (DMSO) LIMKl knockdown increased the sensitivity of the cells to AurKA inhibitor at all concentrations at
both 24 and 48 hr of treatment compared to untranfected PC3
cells only treated withAurKA inhibitor.
In reviewing the detailed disclosure which follows, and the
specification more generally, it should be borne in mind that
all patents, patent applications, patent publications, technical
publications, scientific publications, and other references referenced herein are hereby incorporated by reference in this
application in order to more fully describe the state of the art
to which the present invention pertains.
Reference to particular buffers, media, reagents, cells, culture conditions and the like, or to some subclass of same, is
not intended to be limiting, but should be read to include all
such related materials that one of ordinary skill in the art
would recognize as being of interest or value in the particular
context in which that discussion is presented. For example, it
is often possible to substitute one buffer system or culture
medium for another, such that a different but known way is
used to achieve the same goals as those to which the use of a
suggested method, material or composition is directed.
It is important to an understanding of the present invention
to note that all technical and scientific terms used herein,
unless defined herein, are intended to have the same meaning
as commonly understood by one of ordinary skill in the art.
The techniques employed herein are also those that are known
to one of ordinary skill in the art, unless stated otherwise. For
purposes of more clearly facilitating an understanding the
invention as disclosed and claimed herein, the following definitions are provided.

While a number of embodiments of the present invention
have been shown and described herein in the present context,
such embodiments are provided by way of example only, and
not of limitation. Numerous variations, changes and substitutions will occur to those of skilled in the art without materially departing from the invention herein. For example, the
present invention need not be limited to best mode disclosed
herein, since other applications can equally benefit from the
teachings of the present invention. Also, in the claims, meansplus-function and step-plus-function clauses are intended to
cover the structures and acts, respectively, described herein as
performing the recited function and not only structural
equivalents or act equivalents, but also equivalent structures
or equivalent acts, respectively. Accordingly, all such modifications are intended to be included within the scope of this
invention as defined in the following claims, in accordance
with relevant law as to their interpretation.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 1
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 29
TYPE, DNA
ORGANISM, Unknown
FEATURE,
OTHER INFORMATION, Description of Unknown, LIMKl oligonucleotide

<400> SEQUENCE, 1
29

aaggacaaga ggctcaactt catcactga

15

What is claimed is:
3. The method of claim 1, further comprising administering an additional therapy to said subject prior to, during or
1. A method for treating prostate cancer in a subject, said
subsequent to said administering of said LIMKl and AurKA
method comprising administering a therapeutically effective
inhibitors.
amount of a LIM kinase 1 (LIMKl) inhibitor and an Aurora
20
4. The method of claim 1, wherein said therapeutically
Kinase A (AurKA) inhibitor to said subject, wherein said
effective amount of a LIMKl inhibitor and aAurKA inhibitor
LIMKl inhibitor comprises an antibody that binds to LIMKl,
comprises a dosage of each that is effective for treatment of
and theAurKA inhibitor comprises MLN823 7 or an antibody
the cancer and which is lower than a dosage required to
that binds to AurKA.
2. The method of claim 1, wherein said LIMKl inhibitor is 25 achieve the same level of treatment with only one of the
inhibitors.
an antibody that bind to LIMKl and said AurKA inhibitor is
an antibody that binds to AurKA.
* * * * *

